MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Wit...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/10/1404 |
id |
doaj-1455d62de4534aa9974b33d33e6be087 |
---|---|
record_format |
Article |
spelling |
doaj-1455d62de4534aa9974b33d33e6be0872020-11-25T01:32:44ZengMDPI AGCancers2072-66942019-09-011110140410.3390/cancers11101404cancers11101404MET Inhibitors in Small Cell Lung Cancer: From the Bench to the BedsideMax Hardy-Werbin0Raúl del Rey-Vergara1Miguel Alejandro Galindo-Campos2Laura Moliner3Edurne Arriola4Cancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), 08003 Barcelona, SpainCancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), 08003 Barcelona, SpainCancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), 08003 Barcelona, SpainMedical Oncology Department, Hospital del Mar-CIBERONC, 08003 Barcelona, SpainCancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), 08003 Barcelona, SpainSmall cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Within the potentially interesting targets, the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathway activation is associated with worse survival and chemoresistance in SCLC. Preclinical data suggest that the inhibition of the MET pathway can revert chemoresistance and prevent tumor growth. Recently, immunotherapy has shown modest but relevant activity in SCLC. Interestingly, MET modulation seems to be involved in increasing the efficacy of standard checkpoint inhibitors. Here, we review the preclinical and clinical data of MET inhibition in SCLC, and the role of this pathway in the immune response.https://www.mdpi.com/2072-6694/11/10/1404small cell lung cancerMETHGFimmunotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Max Hardy-Werbin Raúl del Rey-Vergara Miguel Alejandro Galindo-Campos Laura Moliner Edurne Arriola |
spellingShingle |
Max Hardy-Werbin Raúl del Rey-Vergara Miguel Alejandro Galindo-Campos Laura Moliner Edurne Arriola MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside Cancers small cell lung cancer MET HGF immunotherapy |
author_facet |
Max Hardy-Werbin Raúl del Rey-Vergara Miguel Alejandro Galindo-Campos Laura Moliner Edurne Arriola |
author_sort |
Max Hardy-Werbin |
title |
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside |
title_short |
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside |
title_full |
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside |
title_fullStr |
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside |
title_full_unstemmed |
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside |
title_sort |
met inhibitors in small cell lung cancer: from the bench to the bedside |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2019-09-01 |
description |
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Within the potentially interesting targets, the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathway activation is associated with worse survival and chemoresistance in SCLC. Preclinical data suggest that the inhibition of the MET pathway can revert chemoresistance and prevent tumor growth. Recently, immunotherapy has shown modest but relevant activity in SCLC. Interestingly, MET modulation seems to be involved in increasing the efficacy of standard checkpoint inhibitors. Here, we review the preclinical and clinical data of MET inhibition in SCLC, and the role of this pathway in the immune response. |
topic |
small cell lung cancer MET HGF immunotherapy |
url |
https://www.mdpi.com/2072-6694/11/10/1404 |
work_keys_str_mv |
AT maxhardywerbin metinhibitorsinsmallcelllungcancerfromthebenchtothebedside AT rauldelreyvergara metinhibitorsinsmallcelllungcancerfromthebenchtothebedside AT miguelalejandrogalindocampos metinhibitorsinsmallcelllungcancerfromthebenchtothebedside AT lauramoliner metinhibitorsinsmallcelllungcancerfromthebenchtothebedside AT edurnearriola metinhibitorsinsmallcelllungcancerfromthebenchtothebedside |
_version_ |
1725080049059627008 |